癌症对健康、生活质量和经济产生重大影响。筛查可能会降低癌症死亡率和治疗费用，但美国的筛查费用未知。估算2021年美国每年初次癌症筛查（即无后续费用的筛查）费用。模型使用全国医疗保健调查和成本资源数据。美国医疗保健系统和机构。有资格进行乳腺癌、宫颈癌、结直肠癌、肺癌和前列腺癌筛查的人员，并提供可用数据。按 2021 年保险状况划分的筛查人数和相关医疗保健系统成本。初始医疗保健系统总成本2021 年美国的癌症筛查预计将达到 430 亿美元。约 88.3% 的成本归因于私人保险； 8.5% 用于医疗保险； 3.2% 提供给医疗补助、其他政府计划和未参保人员。结直肠癌筛查约占总费用的 64%；筛查结肠镜检查约占总数的55%。设施成本（支付给进行检测的设施的金额）是筛查总估计成本的主要驱动因素。有关癌症筛查的所有数据均基于国家医疗保健调查的自我报告。估算不包括阳性或异常筛查结果的后续费用。尚未完全捕获基于地理位置、提供者或医疗保健组织的成本差异。2021 年美国初次癌症筛查的估计年度成本为 430 亿美元，低于美国报告的第一年癌症治疗的年度成本诊断后12个月。确定癌症筛查成本及其驱动因素对于帮助制定政策和制定计划优先事项至关重要，特别是对于增加获得推荐的癌症筛查服务的机会而言。无。

Cancer has substantial health, quality-of-life, and economic impacts. Screening may decrease cancer mortality and treatment costs, but the cost of screening in the United States is unknown.To estimate the annual cost of initial cancer screening (that is, screening without follow-up costs) in the United States in 2021.Model using national health care survey and cost resources data.U.S. health care systems and institutions.People eligible for breast, cervical, colorectal, lung, and prostate cancer screening with available data.The number of people screened and associated health care system costs by insurance status in 2021 dollars.Total health care system costs for initial cancer screenings in the United States in 2021 were estimated at $43 billion. Approximately 88.3% of costs were attributable to private insurance; 8.5% to Medicare; and 3.2% to Medicaid, other government programs, and uninsured persons. Screening for colorectal cancer represented approximately 64% of the total cost; screening colonoscopy represented about 55% of the total. Facility costs (amounts paid to facilities where testing occurred) were major drivers of the total estimated costs of screening.All data on receipt of cancer screening are based on self-report from national health care surveys. Estimates do not include costs of follow-up for positive or abnormal screening results. Variations in costs based on geography and provider or health care organization are not fully captured.The $43 billion estimated annual cost for initial cancer screening in the United States in 2021 is less than the reported annual cost of cancer treatment in the United States in the first 12 months after diagnosis. Identification of cancer screening costs and their drivers is critical to help inform policy and develop programmatic priorities, particularly for enhancing access to recommended cancer screening services.None.